CLINICAL_TRIALS
trial_result
· 2010-01-26
Clinical Trial Update: Natalizumab Re-Initiation of Dosing [Phase 3]
Summary
Completed Phase 3 study evaluating re-initiation of Natalizumab dosing in relapsing-remitting multiple sclerosis; results have been posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Biogen | Conditions: Multiple Sclerosis, Relapsing-Remitting | Phase 3 | Status: COMPLETED | Results posted: 2010-01-26